3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Unknown
2
Withdrawn
1
Suspended
1
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
11
Lymphoma, Large B-Cell, Diffuse
10
Triple Negative Breast Neoplasms
8
Recurrence
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, B-Cell
6
Neoplasm Metastasis
4
Multiple Myeloma
4
Leukemia, Myeloid, Acute
4
Leukemia
4
Neuroblastoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Hematologic Neoplasms
3
Head and Neck Neoplasms
3
Graft vs Host Disease
3
Squamous Cell Carcinoma of Head and Neck
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Oropharyngeal Neoplasms
2
Neoplasms, Plasma Cell
2
Hodgkin Disease
2
Dendritic Cell Sarcoma, Interdigitating
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Wilms Tumor
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Interventions
Vincristine
1
Prednisone
1
Doxorubicin
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Enteropathy-Associated T-Cell Lymphoma
×
Cyclophosphamide
×
Clear all
NCT06701344
2024-11-22
GOAL
Ruijin Hospital
Phase 2
Not yet recruiting
7 enrolled